Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

caracemide

Known as: Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI), Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI), N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea 
An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryForty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with… Expand
  • table 2
  • table I
2004
2004
Twenty-four previously untreated, ambulatory patients with advanced colorectal carcinoma were treated with either caracemide (11… Expand
  • table 1
  • table 2
2004
2004
SummaryA Phase I study of caracemide evaluating a short intravenous infusion repeated every 21 days is presented. Patients were… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2004
2004
In recent phase 1 clinical trials, caracemide [N-acetyl-N-(methylcarbamoyloxy)-N-methylurea; NSC-253272] has demonstrated a… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
1993
1993
Following administration to rats of a single ip dose (6.6 mg kg-1) of the investigational antitumor agent caracemide (N-acetyl-N… Expand
1992
1992
The anticancer drug caracemide, N-acetyl-N,O- di(methylcarbamoyl)hydroxylamine, and one of its degradation products, N-acetyl-O… Expand
1987
1987
We conducted a phase I trial of caracemide, a new chemotherapeutic agent, which is active in the MX1 (mammary) and CX1 (colon… Expand
1986
1986
Preclinical pharmacologic studies of caracemide [N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea; CAR] have demonstrated a marked… Expand
1986
1986
Because the antitumor drug caracemide causes neuropsychiatric effects in patients, we investigated its effects on the… Expand
1984
1984
: Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from… Expand